

Biperiden

Section

Antiparkinsonism medicines

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

Bromocriptine

Section

Antiparkinsonism medicines

Oral > Solid: 2.5 mg; 5 mg

Indications

Parkinson disease

Cabergoline

Section

Antiparkinsonism medicines

Oral > Solid: 0.5 mg

Indications

Parkinson disease

Dihydroergocryptine mesylate

Section

Antiparkinsonism medicines

Oral > Solid:

Indications

Parkinson disease

Levodopa

Section

Antiparkinsonism medicines

Oral > Solid: 250 mg

Indications

Parkinson disease

Levodopa + carbidopa

Section

Antiparkinsonism medicines

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

Pramipexole

Section

Antiparkinsonism medicines

Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

Parkinson disease

Ropinirole

Section

Antiparkinsonism medicines

Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

Parkinson disease

Trihexyphenidyl

Section

Antiparkinsonism medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Indications

Parkinson disease